The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFLX.L Regulatory News (FLX)

  • There is currently no data for FLX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

20 Dec 2016 13:49

RNS Number : 3843S
Falanx Group Limited
20 December 2016
 

Falanx Group Limited

("Falanx" or "the Company")

 

DIRECTOR DEALINGS AND GRANT OF SHARE OPTIONS

 

Falanx Group (AIM:FLX), the global intelligence, security and cyber defence provider, announces that on 19th December 2016, Stuart Bladen, Chief Executive Officer, acquired 310,000 ordinary shares of no par value ("Ordinary Shares") in the capital of the Company. Mr Bladen's resultant interest following this transaction, which was completed at a price of 7.25 pence per share, is now in 310,000 Ordinary Shares, representing 0.25 per cent of the Company's issued share capital.

 

Falanx also announces that on 6th October 2016 and pursuant to the rules of the Falanx Group Long Term Incentive Plan, the Company granted options to Mr Bladen to subscribe for up to 3,000,000 Ordinary Shares ("Options") as follows:

 

Date from which Options are exercisable, post date of grant: 6th October 2016 ("Date of Grant")

No. of Ordinary Shares over which the Options can be exercised

Earlier of 12 months from the Date of Grant and date at which the share price of the Company has consistently been at 6p or above for 6 months

1,000,000

Earlier of 24 months from the Date of Grant and date at which the Share Price of the Company has consistently been at 12p or above for 6 months

1,000,000

Earlier of 36 months from the Date of Grant and date at which the Share Price of the Company has consistently been at 20p or above for 6 months

1,000,000

 

To the extent that the relevant performance conditions are met as set out above, then the Options can be exercised at 5p per Ordinary Share. Any Options remaining unexercised on 6th October 2019 will automatically lapse.

 

Following the grant of the Options to Mr Bladen, the total number of Ordinary Shares subject to options and which could, in the future, be issued to him is 3,000,000, which represents 2.4% of the current issued share capital of the Company.

 

Enquiries:

 

Falanx Group Limited

Stuart Bladen, Chief Executive Officer

 

 

 

via Walbrook PR

www.falanxgroup.com

www.falanxassuria.com

www.falanxcyberdefence.com

Panmure Gordon (UK) Limited

Nominated Adviser & Joint Broker

Andrew Godber / Peter Steel

 

+44 (0) 20 7886 2500

Whitman Howard Limited

Joint Broker

Nick Lovering / Francis North

 

+44 (0) 207 659 1234

Walbrook PR (Media and Investor Relations) Paul Cornelius / Nick Rome

+44 (0) 207 933 8780

falanx@walbrookpr.com

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail in relation to Mr Bladen's purchase of Ordinary Shares on 19th December 2016.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 

 1

 

Details of the person discharging managerial responsibilities / person closely associated 

a)

 

Names 

Stuart Bladen - Chief Executive Officer

2

 

Reason for the notification

a)

 

Position/status

 

See 1(a) above, Stuart Bladen classified as a PDMR of the Company with effect from 17th October 2016 (the date of Mr Bladen's formal appointment as Chief Executive Officer)

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

 

Name

 

Falanx Group Limited

b)

 

LEI

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Ordinary Shares of no par value

b)

Identification code 

 

VGG3338A1075

c)

 

Nature of the transaction 

 

Purchase of Ordinary Shares

d)

 

Price(s) and volume(s)

Volume(s):

310,000 Ordinary Shares

Price: 7.25 pence per Ordinary Share

d)

 

Aggregated information 

- Aggregated volume

- Price

 N/A

 

e)

 

Date of the transactions 

19th December 2016

f)

 

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

Name of authorised official of issuer responsible for making notification:

 

Mr John Blamire, Director

 

Company Secretary to Falanx Group Limited

 

About Falanx

Falanx Group Limited, is a global intelligence and cyber defence provider working with blue chip and government clients. The Group listed on AIM in June 2013 under ticker FLX For more information: http://www.falanxgroup.com/.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBXBDDISDBGLG
Date   Source Headline
9th Dec 20222:42 pmRNSHolding(s) in Company
8th Dec 20224:29 pmRNSResult of AGM
8th Dec 20227:00 amRNSInterim Results
24th Nov 20225:17 pmRNSHolding(s) in Company
15th Nov 20225:56 pmRNSNotice of AGM
18th Oct 20227:00 amRNSDirectorate Change
29th Sep 20227:00 amRNSFinal Results
20th Sep 20227:00 amRNSHolding(s) in Company
5th Sep 20224:53 pmRNSHolding(s) in Company
4th Aug 20222:06 pmRNSSecond Price Monitoring Extn
4th Aug 20222:00 pmRNSPrice Monitoring Extension
4th Aug 202211:05 amRNSSecond Price Monitoring Extn
4th Aug 202211:00 amRNSPrice Monitoring Extension
4th Aug 20227:00 amRNSTrading Update
9th May 20227:00 amRNSPartnership to Provide M-EDR to UK Customers
8th Apr 20224:06 pmRNSHolding(s) in Company
6th Apr 202211:59 amRNSHolding(s) in Company
1st Apr 20227:00 amRNSChange of Adviser
30th Mar 20222:44 pmRNSDirector/PDMR Shareholding
23rd Mar 202212:59 pmRNSDirector/PDMR Shareholding
10th Feb 202211:11 amRNSDirector/PDMR Shareholding
24th Jan 20227:00 amRNSDirector/PDMR Shareholding
19th Jan 20225:20 pmRNSHolding(s) in Company
19th Jan 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 202111:14 amRNSResult of AGM
7th Dec 20217:00 amRNSInterim Results
16th Nov 20212:10 pmRNSNotice of AGM
29th Oct 20211:57 pmRNSExercise of Options, TVR and PDMR dealing
27th Oct 20219:03 amRNSDirector/PDMR Shareholding
26th Oct 20217:00 amRNSDirector/PDMR Shareholding
25th Oct 20213:25 pmRNSExercise of Options and TVR
13th Oct 202111:06 amRNSSecond Price Monitoring Extn
13th Oct 202111:00 amRNSPrice Monitoring Extension
13th Oct 20217:00 amRNSTrading update and BOOST&Co loan facility update
6th Oct 20214:41 pmRNSSecond Price Monitoring Extn
6th Oct 20214:35 pmRNSPrice Monitoring Extension
6th Oct 20212:43 pmRNSSale of Assynt for £4.6 million
4th Oct 20217:00 amRNSFalanx Launch Mass Market Security Assessment Tool
29th Sep 20217:00 amRNSAnnual results for the year ended 31 March 2021
18th Aug 20217:01 amRNSGrant of share options
18th Aug 20217:00 amRNSTrading Update & New Loan Facility
9th Jul 20219:07 amRNSHolding(s) in Company
29th Apr 20217:00 amRNSCancellation of unapproved Share Options
1st Apr 20217:00 amRNSIssue of Equity and TVR
26th Feb 20213:31 pmRNSResult of GM
10th Feb 20212:03 pmRNSPublication of Circular & Notice of GM
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
5th Feb 20217:00 amRNSContract Wins and Covid Business Interruption Loan
18th Jan 20212:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.